EUVIMEDEUVIMED entdecken
Crossref

Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma

Mikako Tamba, Akihiko Okamura, Hiroki Osumi, Yu Imamura, Jun Kanamori, Mariko Ogura, Shota Fukuoka, Koichiro Yoshino, Shohei Udagawa, Takeru Wakatsuki, Eiji Shinozaki, Masayuki Watanabe und 3 weitere

Esophagus · 2025

DOI: 10.1007/s10388-024-01103-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Esophagus, 2025. Verfasst von Mikako Tamba und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Chemotherapy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 3-8-31 Ariake, Koto-Ku, Tokyo, 13…. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: It remains unclear whether the lymph-node ratio (LNR) is a relevant factor for the risk of recurrence following neoadjuvant chemotherapy (nCT) with docetaxel, cisplatin, and 5-fluorouracil (DCF), which is a new standard of care for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. This study aimed to evaluate the clinical utility of LNR as a risk factor for recurrence. MATERIALS AND METHODS: We retrospectively analyzed 75 patients who underwent nCT-DCF followed by curative surgery for resectable ESCC. The cut-off for the LNR was determined using receiver-operating characteristic curve analysis for recurrence. RESULTS: A higher LNR was observed in 34 (45.3%) patients. At a median follow-up of 19.2 months, the median disease-free survival (DFS)/recurrence-free survival (RFS) rate was not reached in patients with a lower LNR and was 8.0 months in those with a higher LNR (P < 0.01). The estimated 1-year DFS/RFS rate was 47.8% and 100% for patients with a higher LNR and lower LNR, respectively. LNR remained a risk factor, even when stratified by non-pathological complete response, the presence of positive ypN, or ypStage III. In those with a higher LNR, the median DFS/RFS was 18.3 versus 8.0 months with and without adjuvant nivolumab treatment, respectively. CONCLUSIONS: Higher LNR indicates a more aggressive phenotype with worse DFS/RFS rates and increased recurrence following nCT-DCF treatment and curative surgery for ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsLymph Node RatioLymph NodesHumansFemaleMaleFluorouracilCisplatinNeoadjuvant TherapyMiddle AgedDocetaxelRetrospective StudiesRisk FactorsAgedDisease-Free SurvivalJapanAdultLymphatic Metastasis

Stichwörter der Autor:innen

Esophageal squamous cell carcinomaLymph-node ratioNeoadjuvant chemotherapy

Substanzen

FluorouracilCisplatinDocetaxel

Autor:innen und Institutionen

  • Department of Gastroenterological Chemotherapy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
  • Department of Gastroenterological Surgery, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan.
  • Department of Gastroenterological Chemotherapy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan. sp9y9tq9@piano.ocn.ne.jp.

ORCID-Profile: Akira Ooki

Zitieren

APA

Tamba, M., Okamura, A., Osumi, H., Imamura, Y., Kanamori, J., Ogura, M., Fukuoka, S., Yoshino, K., Udagawa, S., Wakatsuki, T., Shinozaki, E., Watanabe, M., Yamaguchi, K., Chin, K., & Ooki, A. (2025). Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma. Esophagus. https://doi.org/10.1007/s10388-024-01103-6

Vancouver

Tamba M, Okamura A, Osumi H, Imamura Y, Kanamori J, Ogura M, et al. Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma. Esophagus. 2025. doi:10.1007/s10388-024-01103-6

BibTeX
@article{Tamba2025,
  author = {Tamba, Mikako and Okamura, Akihiko and Osumi, Hiroki and Imamura, Yu and Kanamori, Jun and Ogura, Mariko and Fukuoka, Shota and Yoshino, Koichiro and Udagawa, Shohei and Wakatsuki, Takeru and Shinozaki, Eiji and Watanabe, Masayuki and Yamaguchi, Kensei and Chin, Keisho and Ooki, Akira},
  title = {Lymph-node ratio as a risk factor for recurrence following neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma},
  journal = {Esophagus},
  year = {2025},
  doi = {10.1007/s10388-024-01103-6}
}
Kostenlos starten →